AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure

AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
  • AstraZeneca Plc AZN laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress.
  • Farxiga (dapagliflozin) led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure over a median follow-up of 2.3 years. 
  • In the placebo group, 19.5% of patients either experienced cardiovascular death or worsened heart failure.
  • Related: AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions.
  • AstraZeneca also presented a pooled analysis of Phase 3 DELIVER and DAPA-HF trials.
  • Farxiga reduced the risk of CV death by 14% over a median follow-up of 22 months. The drug reduced death from any cause by 10%. 
  • First and repeat hospitalization was also reduced by 29%. 
  • The data comes from 11,007 patients, the company said.
  • Farxiga is approved for type 2 diabetes, chronic kidney disease, and certain heart failure patients.
  • Price Action: AZN shares closed lower by 2.84% at $66.32 on Friday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral